Business Wire

Mary Kay Inc. Continues Its Support of Women’s Empowerment at the International Women’s Forum TIME’S UP Virtual Conference

19.5.2020 17:53:00 EEST | Business Wire | Press release

Share

Mary Kay Inc. continues its support of female entrepreneurship, empowerment and thought leadership as a premier sponsor for the 2020 International Women's Forum (IWF) Virtual Cornerstone Conference. Originally scheduled to take place May 13-15, in London, the conference has shifted to a digital format due to the COVID-19 pandemic; much of the same great content and speakers will be broadcast globally in a series of virtual sessions shared weekly at https://www.iwforum.org/.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005709/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carolyn Passey, General Manager, Mary Kay United Kingdom & Ireland (Photo: Mary Kay Inc.)

On May 21, Mary Kay will participate in a virtual session entitled “A Conversation with TIME’S UP UK” discussing important issues such as #MeToo and how the ensuing TIME’S UP movement has led to re-thinking women’s safety on film and television sets, as well as other industries around the world. Carolyn Passey, General Manager of Mary Kay UK and Ireland, will open the session focusing on changes TIME’S UP UK is seeking to implement, navigating the line between personal and professional, and aiding those who frequently find themselves vulnerable and exploited while filming.

“At Mary Kay, we advocate for women’s empowerment and gender equality and we partner with organizations whose mission is to do the same,” said Passey. “Today, as the COVID-19 crisis is exacerbating women's vulnerabilities and gender inequality1, we know trust and safety are more critical than ever for women to thrive. The workplace should be a safe and dignified place for all of us. How can we ensure—and demand—this happens? I look forward to the discussion on the topic with thought leaders from around the world.”

Speakers at the session include:

  • Dame Heather Rabbatts, TIME’S UP UK Chair Managing Director of Cove Pictures; Chair of Soho Theatre and non-executive board member for Arts Alliance.
  • Ita O’Brien, the UK’s leading Intimacy Coordinator and founder of Intimacy on Set, her company through which she has been developing best practices regarding intimacy and nudity in film, television and theatre and through which she trains Intimacy Coordinators all over the world.

“Now, more than ever, it is crucial to continue the conversation around safe and equal working conditions for women within the entertainment industry and beyond,” said Stephanie O’Keefe, CEO of IWF. “As the world develops a new way to work in the context of COVID-19, I am hopeful that there will be strategies in place to ensure women can re-enter the physical workplace with confidence they will be safe and treated equally. Mary Kay is a long-time supporter of gender equality, and we are thrilled to continue this fight with them to ensure a more gender-equal world.”

A link to watch the event will be available on the IWF website and its YouTube page May 26: https://www.youtube.com/channel/UCdLPNS7ai1_XHaqgEnhEjtg

1 United Nations Secretary-General’s Policy Brief on The Impact of COVID-19 on Women, April 9, 2020
https://www.un.org/sites/un2.un.org/files/policy_brief_on_covid_impact_on_women_9_apr_2020_updated.pdf
and - Blog article by United Nations Foundation, Blog article from Michelle Milford Morse and Grace Anderson, April 14, 2020
https://unfoundation.org/blog/post/shadow-pandemic-how-covid19-crisis-exacerbating-gender-inequality/

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

About International Women’s Forum (IWF) and the Leadership Foundation

IWF is an invitation-only membership organization of more than 7,000 diverse and accomplished women from 33 nations on six continents. IWF advances women’s leadership and champions equality worldwide by connecting accomplished women both globally and locally. Members include Fortune 500 executives, government leaders from the local to sovereign level, international nonprofit leaders, and luminaries from the academy, arts and sciences. For more information, please visit www.iwforum.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye